Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations.
Regulatory News:
Median Technologies (Paris:ALMDT):
Total number of shares | 38,202,387 |
Number of real voting rights* (excluding treasury shares**) | 38,143,292 |
Theoretical number of voting rights* (including treasury shares**) | 38,179,187 |
(*) Class E preference shares are non-voting
(**) pursuant to article 223-11 of the AMF's General Regulations
Furthermore, as of May 27, 2026, out of the 14,424,541 warrants (BSA) issued in connection with the 2025 capital increase, 12,325,725 remained outstanding and exercisable.
About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260608624521/en/
Contacts:
Median Technologies
Emmanuelle Leygues
VP, Corporate Marketing Financial Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com
Investors SEITOSEI ACTIFIN
Ghislaine Gasparetto
+33 6 85 36 76 81
ghislaine.gasparetto@seitosei-actifin.com
Press MAARC
Bruno Arabian
+33 6 87 88 47 26
bruno.arabian@maarc.fr
